Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder while Breastfeeding
Most health expert recommend six month of exclusive breastfeeding but statics suggest that numbers are not good, almost 95% mothers start breastfeeding but this number drops to 40% in first three month and further it drops to 15% till fifth month. Sometime its due to need of medication usage. Because of these statics its important to provide good information on safety of drugs in breastfeeding so that it can be improved when possible. In this FAQ sheet we will discuss about exposure to Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder while breastfeeding. We will also discuss about common side effects and warnings associated with Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder.

What is Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder used for?


helps prevent sunburn higher SPF gives more sunburn protection

Brief: Active ingredients Purpose OCTINOXATE 1.9% Sunscreen TITANIUM DIOAXIDE 15.0% Sunscreen

Can I continue breastfeeding if I am using Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder? How long does it stays in breast milk?

Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder high risk while breastfeeding
Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder consists two active ingredients Octinoxate and Titanium dioxide and as per our analysis of both we have determined the Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder is unsafe during breastfeeding. We recommend you to check both ingredients below for better understanding of Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder in breastfeeding.

Octinoxate and Breastfeeding

Unsafe

Octinoxate (Octylmethoxycinnamate) has been detected in human urine, blood and breast milk and is known for moderate risk of skin allergy. Some studies suggest that Octinoxate has estrogen like effects however less than 1% skin penetration has been found in human laboratory studies. As not much study has been done on effects of Octinoxate during breast feeding its recommended to use safe alternatives.

Octyl Methoxycinnamate (OMC) is a frequently used UV-filter in sunscreens and other cosmetics. Octinoxate can be systemically absorbed after skin application, being found in the deeper layers of the stratum corneum as well as urine, plasma, and breast milk. The mean maximum plasma concentration detected after application of 2mg/cm2 sunscreen was 7ng/mL in women and 16ng/mL in men. FDA study found blood levels 13 times above cutoff for systemic exposure.

Several studies indicated that OMC acts as an endocrine disruptor due to the ability to interfere with endocrine system at different levels. In humans OMC exposure has minor, but statistically significant effects on the levels of testosterone and estradiol. Moreover, some studies suggested that OMC can interact with the hypothalamo-pituitary-thyroid (HPT) axis.

Moreover, a study of offspring of dams treated with OMC (500�1000 mg/kg/day) showed sex-dependent behavioral changes, namely decreased motor activity in females, but not in males, and improved spatial learning in males, suggesting that OMC can affect neuronal development, however the doses used in these experiments were extremely high, not relevant to possible human exposure.

Note: Study and data for tropical use only

Warning: High dosage shall be avoided as reproductive system, thyroid and behavioral alterations in animal studies has been found, Tropical usage in breast area shall be avoided to prevent the OCTINOXATE passing orally in Infants.

Titanium dioxide and Breastfeeding

Low Risk

Not much study has been done on effects of topical usage of Titanium Dioxide during breast feeding but as there is no finding of Titanium Dioxide passing in breast milk its unlikely to cause any health issue for infant.

Some animal studies suggest that maternal exposure to titanium dioxide nanoparticles during pregnancy and lactation alters offspring hippocampal mRNA BAX and Bcl-2 levels, induces apoptosis and decreases neurogenesis. But dosage was significantly higher than daily possible exposure to humans.

Note: Study and data for tropical use only. Inhalation concerns in powder or spray products.

Warning: Tropical usage in breast area shall be avoided to prevent the Titanium Dioxide passing orally in Infants. Titanium dioxide is possibly carcinogenic to humans. Titanium dioxide can be drastically more harmful if used as powder or spray as risk of inhalation can increase significantly.


What should I do if already breastfed my kid after using Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder?

We have already established that Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder is unsafe in breastfeeding and breastfeeding while using Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder is not a good idea however if have already used and then breastfed the baby then you shall monitor the behavior and health of baby closely and inform your doctor as soon as possible. In case of emergency please call 911.


My doctor has prescribed me Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder, what should I do?

If your doctor knows that you are breastfeeding mother and still prescribes Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder then there must be good reason for that as Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder is considered unsafe, It usually happens when doctor finds that overall advantage of taking outweighs the overall risk.


If I am using Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder, will my baby need extra monitoring?

Yes, Extra monitoring is required if mother is using Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder and breastfeeding as it is considered unsafe for baby.


Who can I talk to if I have questions about usage of Cle De Peau Beaute Bf20 | Octinoxate And Titanium Dioxide Powder in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week

Drug Brands with same Active ingredients